| Literature DB >> 35138438 |
Samineh Beheshtirouy1, Elnaz Khani1, Sajad Khiali1, Taher Entezari-Maleki2,3.
Abstract
In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19. A brief insight about antivirals would help clinicians to choose the best medication for the treatment of COVID-19. In this review, we discuss both novel and repurposed investigational antivirals, focusing on in vitro, in vivo, and clinical trial studies.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35138438 DOI： 10.1007/s00705-022-05368-z
Source DB: PubMed Journal: Arch Virol ISSN： 0304-8608 Impact factor: 2.574